Dextera Biosciences is pioneering a new class of therapeutics—dexabodies—built entirely from D-amino acids to overcome the key limitations of existing drug modalities
Dextera Biosciences is pioneering a new class of therapeutics—dexabodies—built entirely from D-amino acids to overcome the key limitations of existing drug modalities. Unlike traditional biologics, dexabodies are completely resistant to degradation by the body's natural L-enzymes, yet retain antibody-like specificity at just 1/20th the size. This stable, compact format enables unmatched target engagement, deep tissue penetration, and rapid clearance, unlocking superior efficacy, safety, and dosi